Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cytokine therapy for hematological malignancies

K Ezaki1, M Tsuzuki

  • 1Department of Internal Medicine, Fujita Health University School of Medicine, Aichi, Japan.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|May 1, 1997
PubMed
Summary

Interferon-alpha (IFN-a) shows significant antitumor effects in hematological malignancies, particularly chronic myeloid leukemia (CML). Colony-stimulating factors (CSFs) effectively reduce neutropenia and infections after chemotherapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Activation of p38 mitogen-activated protein kinase is required for in vivo brain-derived neurotrophic factor production in the rat hippocampus.

Neuroscience·2009
Same author

Clinical characteristics and outcomes in patients with t(8;21) acute myeloid leukemia in Japan.

Leukemia·2007
Same author

Apical vulnerability to dendritic retraction in prefrontal neurones of ageing SAMP10 mouse: a model of cerebral degeneration.

Neuropathology and applied neurobiology·2006
Same author

SspA, an outer membrane protein, is highly induced under salt-stressed conditions and is essential for growth under salt-stressed aerobic conditions in Rhodobacter sphaeroides f. sp. denitrificans.

Applied microbiology and biotechnology·2005
Same author

Hsp27 suppresses the formation of inclusion bodies induced by expression of R120G alpha B-crystallin, a cause of desmin-related myopathy.

Cellular and molecular life sciences : CMLS·2003
Same author

[Early phase II clinical trial of amrubicin hydrochloride in patients with malignant lymphoma].

Gan to kagaku ryoho. Cancer & chemotherapy·2001

Area of Science:

  • Hematology
  • Oncology
  • Immunotherapy

Background:

  • Cytokines are increasingly used in treating hematological malignancies.
  • Interferon (IFN) and colony-stimulating factors (CSFs) are key cytokines in this field.

Purpose of the Study:

  • To review the therapeutic roles of IFN and CSFs in hematological malignancies.
  • To discuss the mechanisms and clinical applications of these cytokines.

Main Methods:

  • Review of existing studies on IFN-a and CSFs in hematological cancers.
  • Analysis of clinical trial data regarding efficacy and safety.

Main Results:

  • IFN-a demonstrates significant antitumor activity in chronic phase CML, with notable cytogenetic responses and potential for long-term survival.

Related Experiment Videos

  • CSFs effectively shorten neutropenia, reduce infections, and decrease hospitalization in patients undergoing chemotherapy or stem cell transplantation.
  • CSFs aid in mobilizing peripheral blood stem cells and increasing chemotherapy dose intensity.

    • Conclusions:

    • IFN-a is a valuable treatment for hematological malignancies, though its role alongside bone marrow transplantation requires careful consideration.
    • CSFs are safe and effective in improving neutrophil recovery in acute myelogenous leukemia (AML) patients post-chemotherapy.
    • While CSFs can sensitize leukemic cells to chemotherapy, robust evidence is still lacking.